Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2021 Results - Earnings Call Transcript
02:50pm, Wednesday, 05'th May 2021
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q1 2021 Results - Earnings Call Transcript
Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates
10:09am, Wednesday, 05'th May 2021
Clovis (CLVS) delivered earnings and revenue surprises of 11.11% and -15.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Clovis: On The Verge Of A Major Breakout?
02:02am, Friday, 16'th Apr 2021
Since July 7, 2017, Clovis has lost close to 93% of its value. Shorts have amassed a 32 million share position, but tables can turn quickly. The company has been hemorrhaging cash developing its pipel
Clovis Oncology: Your Keys To Banking Profits
03:59am, Tuesday, 13'th Apr 2021
Clovis Oncology is a highly volatile stock that rises and falls cyclically. Despite Rubraca's approval for two deadly cancer indications (ovarian and prostate), sales have been increasing modestly.
Why Is Clovis (CLVS) Up 4.4% Since Last Earnings Report?
12:07pm, Thursday, 25'th Mar 2021
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
CLVS Stock Price Increased 47.74%: Why It Happened
08:30am, Sunday, 21'st Mar 2021
The stock price of Clovis Oncology Inc (NASDAQ: CLVS) increased by 47.74% on March 19. This is why it happened.
Why Clovis Oncology Stock Skyrocketed Today
04:30pm, Friday, 19'th Mar 2021
The biotech's experimental cancer treatment demonstrated promising results in a clinical trial.
Clovis Oncology Stock Rallies: Technical Levels To Watch
01:48pm, Friday, 19'th Mar 2021
Clovis Oncology Inc. (NASDAQ:CLVS) shares are gaining ground in Friday's session. The jump in the shares comes after a company announcement stating that Rubraca significantly improves progression-fr
Why Clovis Oncology, Marker Therapeutics, Alector Are Rallying Friday
12:43pm, Friday, 19'th Mar 2021
Clovis Oncology, Inc. (NASDAQ: CLVS), Marker Therapeutics, Inc. (NASDAQ: MRKR) and Alector, Inc. (NASDAQ: ALEC) are among the biggest biotech gainers Friday. Clovis Jumps On Ovarian Cancer Data: Clovi
CLVS Stock: Why Cancer-Fighting Clovis Oncology Is Soaring Today
11:19am, Friday, 19'th Mar 2021
Biotech company Clovis Oncology has shown promising info regarding the treatment of ovarian cancer. CLVS stock has benefitted from the data.
Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint
08:19am, Friday, 19'th Mar 2021
Shares of Clovis Oncology Inc. shot up 17.1% in premarket trading Friday, after the biopharmaceutical company said data from a Phase 3 trial demonstrated that its oral Rubraca "significantly improves"
CLVS Stock Price Increases Over 10% Pre-Market: Why It Happened
08:19am, Friday, 19'th Mar 2021
The stock price of Clovis Oncology Inc (NASDAQ: CLVS) increased by over 10% pre-market. This is why it happened.
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place t
Clovis Oncology Survived One Crisis Only to Face Another
10:21am, Wednesday, 10'th Mar 2021
CLVS stock should attract buyers because declining coronavirus cases offer more opportunities to serve cancer patients. But the economic narrative confirms that the bears may have a point in their pes
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q4 2020 Results - Earnings Call Transcript
02:25pm, Tuesday, 23'rd Feb 2021
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q4 2020 Results - Earnings Call Transcript
